The global tumor ablation market is expanding rapidly as rising cancer incidence and demand for less invasive treatment alternatives reshape oncology care worldwide. New industry research values the market at USD 1,922.5 million in 2025, with growth projected to reach USD 4,947.2 million by 2033, representing a robust CAGR of 12.54% during the forecast period, one of the strongest growth rates in the medical device sector.
Precision Treatment Without Traditional Surgery
The tumor ablation market involves the development, production, and application of medical technologies and procedures used to treat cancer by targeting and destroying tumors without the need for traditional surgery. These procedures are typically minimally invasive, offering patients less risk, faster recovery, and a more targeted treatment approach. The market includes manufacturers, healthcare providers, and researchers advancing technologies that are steadily gaining acceptance among oncology providers for their ability to target tumors with minimal disruption to surrounding healthy tissue.
Rising Cancer Burden Fuels Market Expansion
The rising global incidence of cancer is the foremost driver of market growth, boosting demand for effective, minimally invasive treatment options that offer less risk and faster recovery compared to traditional surgery. In July 2026, the World Health Organization projected an annual increase in new cancer cases, with the global toll reaching 35 million by 2050, while highlighting significant inequities in cancer outcomes: five-year survival exceeds 85% in high-income countries but falls below 45% in low-income countries, underscoring the need for stronger health systems and equitable access to care.
An aging global population is compounding this trend. The World Health Organization projects that by 2030, one in six people globally will be aged 60 or older, with this population growing to 1.4 billion, doubling to 2.1 billion by 2050, and those aged 80 and above tripling to 426 million. Since cancer risk increases with age, this demographic shift is generating sustained demand for effective, minimally invasive cancer treatments including tumor ablation.
Cost Remains a Barrier to Global Access
High treatment costs present a significant challenge, particularly in low-income regions where access to advanced healthcare remains limited. While effective, tumor ablation procedures can be expensive, making them difficult for many patients to afford. Potential solutions include improving healthcare reimbursement policies and expanding insurance coverage for minimally invasive procedures, alongside lowering technology costs through innovation, increased competition, and partnerships with global health organizations. Regulatory clearances continue to expand access: in December 2025, Francis Medical received FDA 510(k) clearance for its Vanquish Water Vapor Ablation System for prostate tissue ablation, while in December 2024, AngioDynamics received FDA clearance for its NanoKnife System, a non-thermal, minimally invasive prostate cancer treatment offering a cost-effective alternative that improves patient access.
Technology Advances Improve Precision and Safety
Technological advancement is significantly enhancing treatment outcomes and patient safety across the industry. Innovations in imaging and ablation technologies have improved precision, enabling more targeted tumor destruction with minimal damage to surrounding healthy tissue, while real-time monitoring allows clinicians to assess treatment effectiveness during procedures and reduce risk. In September 2025, Techsomed received FDA 510(k) clearance for the expansion of its BioTraceIO360 AI-powered image-guided therapy platform used in kidney ablation, enabling clinicians to verify and document minimally invasive procedures with greater precision and consistency. In March 2024, Medtronic received FDA clearance for its OsteoCool 2.0 bone tumor ablation system, featuring multi-probe capabilities and enhanced cooling mechanisms that improve treatment flexibility and safety.
The growing use of tumor ablation in treating early-stage cancers represents another key trend, particularly for patients who may not be ideal surgical candidates due to age or comorbidities. In August 2024, IceCure Medical’s research highlighted the acceptance and effectiveness of cryoablation for early-stage breast cancer in non-surgical patients, demonstrating high patient acceptance and successful treatment outcomes.
Segment-Level Insights
By technology, radiofrequency ablation led the market in 2025, reaching a valuation of USD 531.8 million, registering robust expansion due to its cost-effectiveness and precision in targeting tumor cells while minimizing damage to surrounding tissue. By application, liver cancer secured the largest revenue share at 34.55% in 2025, driven by the rising number of liver cancer cases and advancements in ablation technologies that offer precision and reduced recovery times for unresectable tumors. In October 2025, Gunze Medical signed an exclusive distribution agreement with HistoSonics to bring its noninvasive histotripsy ultrasound therapy platform to Japan, expanding access to innovative liver cancer treatment technology.
By treatment type, laparoscopic ablation is poised for the strongest growth, registering a projected CAGR of 13.75% through the forecast period, owing to its minimally invasive nature and enhanced precision that allows surgeons to directly visualize and target tumors through small incisions.
Regional Landscape
North America accounted for approximately 36.56% of the global market in 2025, with a valuation of USD 702.9 million, driven by advanced healthcare infrastructure, extensive research and development, and high adoption of innovative ablation technologies. The region benefits from a strong presence of leading market players offering radiofrequency, microwave, and cryoablation options, alongside supportive government initiatives and favorable reimbursement policies.
Asia Pacific is emerging as the fastest-growing region, driven by rising cancer prevalence, improving healthcare infrastructure, and increasing adoption of advanced medical technologies, with the market projected to expand at a CAGR of 13.64% and reach USD 877.5 million by 2033. Growing awareness of minimally invasive treatments, expanding healthcare access across China, India, and Japan, and rising medical tourism are further fueling regional growth.
Competitive Landscape
The tumor ablation market remains fragmented, with prominent players including Medtronic, Boston Scientific Corporation, AngioDynamics, EDAP TMS S.A., Chongqing Haifu Medical Technology Co., Ltd., Mermaid Medical, HealthTronics, Inc., and HistoSonics, among others. Companies are pursuing partnerships, mergers, acquisitions, and product innovation to expand market share. In July 2026, HistoSonics received CE mark approval for its Edison Histotripsy System, enabling commercialization across Europe for noninvasive treatment of liver tumors, backed by clinical trial data demonstrating a 90% local tumor control rate at 12 months. In February 2026, AngioDynamics expanded European indications for its NanoKnife System to include soft tissue ablation for liver, pancreas, kidney, and prostate tumors, including intermediate-risk prostate cancer.
Outlook
With a projected CAGR of 12.54% through 2033, the tumor ablation market is positioned to become an increasingly central pillar of oncology care as rising cancer incidence, an aging global population, and continued technological innovation converge. As regulatory approvals expand indications and imaging-guided precision continues to improve, tumor ablation is set to capture a growing share of cancer treatment protocols, particularly for patients seeking alternatives to traditional surgery.
